

Characteristics, Treatment and Healthcare Resource Utilisation in Patients diagnosed with Neuropathic or Chronic Pain Using Primary Care Electronic Health Records in the United Kingdom (UK)

First published: 29/06/2022

Last updated: 23/04/2024

Study

Planned

Administrative details

EU PAS number

EUPAS47913

Study ID

49167

DARWIN EU® study

No

Study countries

☐ United Kingdom

Study status

Planned

Research institutions and networks

Institutions

OPEN Health

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

David Price dprice@opri.sg

Study contact

dprice@opri.sg

Primary lead investigator

David Price

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 13/06/2022

Study start date

Planned: 31/08/2022

Date of final study report

Planned: 31/12/2022

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

Grunenthal Limited

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology

Main study objective:

To describe the characteristics and treatments for patients with a diagnosis of peripheral neuropathic pain, diabetic neuropathic pain, trigeminal neuralgia or chronic intractable pain in primary care in the UK.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Medical condition to be studied

Neuralgia

Pain

Population studied

Age groups

- Adults (18 to < 46 years)
- Adults (46 to < 65 years)

- Adults (65 to < 75 years)
 - Adults (75 to < 85 years)
 - Adults (85 years and over)
-

Estimated number of subjects

11700

Study design details

Outcomes

To estimate the HCRU and associated costs of managing patients with peripheral neuropathic pain, diabetic neuropathic pain, trigeminal neuralgia or chronic intractable pain in the UK.

Data analysis plan

Descriptive Analyses All analyses will be descriptive and carried out using Microsoft SQL, R, Stata 14 (StataCorp LLC) and Microsoft Excel. Treatment, HCRU and costs will be summarised aggregating available patients' follow-up as follows: a) By calendar year (e.g. 2017-2018) b) By 3-calendar years of data aggregated (e.g. 2017-2020) c) For the calendar years April 2019 – March 2020 and April 2020 – March 2021 separately to describe the pre- and post-COVID-19 periods. d) By number of patient-years since index pain diagnosis, at 1, 2, and 3 patient-year post-index date

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Optimum Patient Care Research Database

Data sources (types)

[Electronic healthcare records \(EHR\)](#)

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No